Filing Flows › Health Care › Veru (VERU)
Veru (VERU) earnings and revenue breakdown
Latest: Q4 FY24 · 10-K filed Dec 16, 2024 · Veru (VERU) Q4 FY24 earnings results →
Q4 FY24 Revenue up 72% year over year to $6.7M · 128¢ of every $1 of revenue lost · operating margin -112.1%
Veru made $6.7M in Q4 FY24 (+72% Y/Y). Operating margin -112.1%, net loss $8.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Dec 16, 2024.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $6.7M in Q4 FY24, up 72% year over year and up 68% from the previous quarter.
Gross margin was 40.4%, up 0.5 points from a year earlier. Operating costs exceeded revenue by $7.5M, an operating margin of -112.1%. Operating expenses grew 4% against revenue growth of 72%. The quarter ended with a net loss of $8.5M, narrower than the previous quarter's $11.0M loss.
Operating cash flow was −$4.4M. Non-cash charges added back $65K of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items added $873K. Capital expenditures of $63K exceeded it, leaving free cash flow of −$4.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 FY24 | 10-K | Dec 16, 2024 | $6.7M | +72% | -112.1% | −$8.5M | −$4.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Veru
We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (“SARM”), is being developed for two indications: (i) as a treatment to augment fat loss and to prevent lean mass (muscle) loss in sarcopenic obese or overweight older patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, as a treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting.
In its own words, from its 10-K, filed Dec 16, 2024.
Veru against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +72% against the peers' median +10%. Operating margin: -112.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VERU Veru | Q4 FY24 | $6.7M | +72% | -112.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Veru 10-K on SEC EDGAR · CIK 863894 · Pharmaceutical Preparations
13F: who owns VERU and who is buying
More on VERU
History
Every quarter: Q4 FY24 results